

Reference number(s)
1842-A

SPECIALTY GUIDELINE MANAGEMENT

GILENYA (fingolimod hydrochloride) TASCENSO ODT (fingolimod lauryl sulfate) fingolimod hydrochloride (generic)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

All other indications are considered experimental/investigational and not medically necessary.

II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

III. CRITERIA FOR INITIAL APPROVAL

A. Relapsing forms of multiple sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

B. Clinically isolated syndrome

Authorization of 12 months may be granted to members for treatment of clinically isolated syndrome of multiple sclerosis.

IV. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted to members who are experiencing disease stability or improvement while receiving the requested medication.

V. OTHER

Members will not use the requested medication concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).

Reference number(s)
1842-A

VI. REFERENCES

1. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2024.
2. Fingolimod [package insert]. Weston, FL: Apotex Corp.; June 2024.
3. Tascenso ODT [package insert]. Swindon, UK: Catalent Pharma Solutions (UK); June 2024.